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VEGF & endostatin in coronary artery disease
Background/Purpose: Vascular endothelial growth factor (VEGF) and endostatin are related to ischemic
heart disease. This study investigated pericardial fluid and serum levels of VEGF and endostatin in patients
with or without ischemic heart disease.
Methods: A total of 39 patients (24 patients in the CAD group with significant coronary artery disease; 15
patients in the non-CAD group without coronary artery disease) undergoing open heart surgery were enrolled.
In the CAD group, patients were classified according to good coronary collateralization (Group A; n = 11) or
poor coronary collateralization (Group B; n = 13). Pericardial fluid and serum samples were obtained at the
time of surgery. VEGF and endostatin were measured by enzyme-linked immunosorbent assay.
Results: The levels of endostatin in both serum and pericardial fluid were significantly lower in the CAD
group than in the non-CAD group (130.5 ± 37.3 ng/mL vs. 172.4 ± 37.8 ng/mL and 119.0 ± 25.0 ng/mL vs.
143.0 ± 23.5 ng/mL). The concentration of serum VEGF in the CAD group (92.6 ± 18.2 pg/mL) was significantly
higher than that in the non-CAD group (75.2 ± 22.3 pg/mL). The concentration of serum VEGF in Group A
(100.1 ± 20.7 pg/mL) was significantly higher than that in Group B (84.3 ± 12.4 pg/mL). The levels of
pericardial fluid VEGF, serum and pericardial fluid endostatin were not significantly different between Groups
A and B.
Conclusion: Patients with coronary artery disease have lower serum and pericardial fluid levels of endostatin
and higher serum levels of VEGF. Serum level VEGF, but not endostatin, is associated with good or poor
collateralization in patients with coronary artery disease. [J Formos Med Assoc 2006;105(5):377–383]
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The heart is not only a target of neurohormonal
activity, but also an active endocrine and paracrine
organ.1 The cardiac tissue produces many phy-
siologically active substances such as cytokines,
growth factors and cardiac hormones.2 These se-
creted substances may be carried out into the peri-
cardial space.2 Therefore, analysis of pericardial
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fluid provides a modality to elucidate the patho-
physiology of the heart. Endostatin is a potent en-
dogenous angiogenesis inhibitor and an effective
inhibitor of tumor growth in animal models.3–7
Endostatin exhibits strong antiangiogenic ac-
tivity by inhibiting proliferation and migration
of endothelial cells, in addition to inducing endo-
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sified according to the presence of coronary col-
lateralization of grade 2 and 3 (Group A, good col-
lateral circulation) or of grade 0 and 1 (Group B,
poor collateral circulation). Two observers assessed
the coronary cineangiograms in a blinded fashion
and reached a consensus regarding the collateral
filling.
Study protocol
Immediately following incision of the pericar-
dium, undiluted pericardial fluid and blood sam-
ples from the brachial vein were obtained prior to
heparinization. The pericardial fluid and blood
samples were collected in sterile tubes, placed im-
mediately on ice, clarified by centrifugation at
3000g for 10 minutes at 4°C, and rapidly frozen
at –80°C. Concentrations of endostatin and VEGF
in pericardial fluid and serum were measured by
an enzyme-linked immunosorbent assay (R&D
Systems, Minneapolis, MN, USA). The mean min-
imum detectable levels for endostatin and VEGF
were 23 pg/mL and 5 pg/mL, respectively. Absorb-
ance was measured by optical densitometry at
450 nm.
Data collection and statistical analysis
Data collected preoperatively from medical charts
included demographic data and medical history
with emphasis on risk factors. Categorical demo-
graphic data were compared by Fisher’s exact test.
Continuous variables were expressed as mean
± standard deviation, and compared by Student’s
t test and multivariate stepwise logistic regression.
A p value < 0.05 was considered to be statistically
significant.
Results
Among the 24 patients with CAD (22 men, 2
women; mean age, 62.1 ± 9.3 years), 13 had stable
angina and the remaining 11 had acute coronary
syndrome. Unstable angina, non-ST segment ele-
vation or ST-segment elevation myocardial infarc-
tion was defined as acute coronary syndrome. The
demographics and clinical presentations among
thelial cell apoptosis.3,8 Elevated serum endostatin
is associated with tumor vascularity and poor out-
come in a variety of malignancies.9–11
Vascular endothelial growth factor (VEGF) is
an angiogenic growth factor that is implicated in
both physiologic and pathologic angiogenesis.12,13
It is elevated in patients with acute myocardial in-
farction and coronary heart disease.14,15
Patients with ischemic heart disease or coro-
nary artery disease (CAD) have reduced pericar-
dial levels of endostatin.16 It is not known whether
serum levels of endostatin correlate with peri-
cardial endostatin in these patients with ischemic
heart disease. Furthermore, previous studies have
not investigated the pericardial level of endosta-
tin in patients with non-ischemic heart disease.
This study investigated both serum and pericardial
levels of endostatin and VEGF in patients with or
without ischemic heart disease.
Methods
Patients
This study included 39 patients undergoing open
heart surgery. The CAD group consisted of 24
patients with ischemic heart disease undergoing
coronary artery bypass grafting (CABG), and the
non-CAD group consisted of 15 patients with non-
ischemic heart disease. This study was approved
by the institutional review board of this hospital.
All subjects gave written informed consent. Pa-
tients with a prior history of CABG, evidence of
ongoing malignancy or neoplasm, or infection
were excluded.
Coronary angiography
All patients were referred for selective coronary
angiography within 1 month before open heart
surgery for evaluation of coronary lesions and col-
lateral circulation. A significant coronary stenosis
was defined as > 70% narrowing of a major coro-
nary artery branch or > 50% narrowing of the left
main coronary artery. Collateral circulation was
graded on a scale of 0 to 3 as described by Rentrop
et al.17 In the CAD group, patients were further clas-
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patients in the CAD group are summarized in
Table 1. No significant difference in patient char-
acteristics and clinical presentations were evident
between groups A and B. The number of patients
with hyperlipidemia and the use of lipid-lowering
therapy (statin) were similar between the two
groups. The CAD group comprised patients with
either stable angina or acute coronary syndrome.
These two syndromes had a similar prevalence in
the two groups. The extent of CAD is summarized
in Table 2. Patients in Group A had significantly
more occluded arteries (100% vs. 31%) and re-
gional wall motion abnormality (73% vs. 23%)
than patients in Group B. The number of diseased
vessels with > 70% stenosis, ejection fraction,
and number of coronary vessels involved were
similar in the two groups.
Of the 15 patients in the non-CAD group (10
men, 5 women; mean age, 58.9 ± 14.4 years), five
had mitral valve disease, nine had aortic valve
disease, and one had atrial septal defect. There was
a lower prevalence of coronary risk factors in-
cluding diabetes (7% vs. 62%), hypertension (7%
vs. 62%), hyperlipidemia (7% vs. 58%), and smok-
ing (14% vs. 42%) in the non-CAD group com-
pared with the CAD group.
As shown in Figure 1, the concentration of se-
rum VEGF in the CAD group (92.6 ± 18.2 pg/mL)
was significantly higher (p < 0.05) than in the non-
CAD group (75.2 ± 22.3 pg/mL). The concentra-
tion of VEGF in pericardial fluid was similar in both
groups (28.0 ± 8.6 pg/mL and 32.2 ± 11.5 pg/mL,
respectively; p = NS). In these two groups of pa-
tients with or without ischemic heart disease, the
Table 1. Demographics and clinical characteristics of coronary artery disease patients with good
(Group A) or poor (Group B) collateral circulation
Group A (n = 11) Group B (n = 13) p
Age (yr) 62.2 ± 8.9 62.1 ± 9.8 NS
Male/female 10/1 12/1 NS
Diabetes (n) 7 8 NS
Hypertension (n) 8 7 NS
Hyperlipidemia (n) 7 7 NS
Smoking (n) 5 5 NS
Previous MI* (n) 6 6 NS
Stable angina (n) 6 7 NS
Unstable angina (n) 2 2 NS
Acute MI (n) 3 4 NS
Enzyme positivity† (n) 3 4 NS
Previous PCI (n) 4 4 NS
*Including unstable angina and myocardial infarction; †elevation in troponin I. MI = myocardial infarction; PCI = percutaneous coronary
intervention; NS = not significant.
Table 2. Extent of coronary artery disease in patients with good (Group A) or poor (Group B)
collateral circulation
Group A (n = 11) Group B (n = 13) p
Number of diseased vessels > 70% 2.9 ± 0.3 2.9 ± 0.3 NS
Three-vessel disease (n) 10 120 NS
Left main disease > 50% 04 4 NS
Occluded coronary arteries (n) 11 4 00.0006
Regional wall motion abnormality* (n) 08 3 0.038
Ejection fraction % (mean ± SD) 58.9 ± 9.90 57.9 ± 13.9 NS
*Regional wall motion abnormality indicates presence of hypokinesia, akinesia or dyskinesia of segmental wall of left ventricle during
left ventriculography. NS = not significant; SD = standard deviation.
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concentration of VEGF in serum was significantly
higher (p < 0.001) than in pericardial fluid. The
concentration of serum endostatin was significantly
lower (p < 0.005) in the CAD group (130.5 ± 37.3
ng/mL) than in the non-CAD group (172.4 ± 37.8
ng/mL). The level of endostatin in pericardial flu-
id was also significantly lower (p < 0.01) in the
CAD group (119 ± 25 ng/mL) than in the non-
CAD group (143.0 ± 23.5 ng/mL). In both the CAD
and non-CAD groups, the level of endostatin in
serum was not significantly different from that in
pericardial fluid.
As shown in Figure 2, the concentration of se-
rum VEGF in Group A (100.1 ± 20.7 pg/mL) was
significantly higher (p < 0.05) than that in Group
B (84.3 ± 12.4 pg/mL). The concentration of VEGF
in pericardial fluid was similar in both groups
(27.0 ± 10.2 pg/mL and 28.9 ± 7.3 pg/mL, re-
spectively; p = NS). In both of these groups, the
concentration of VEGF in serum was significantly
higher (p < 0.001) than that in pericardial fluid.
The level of endostatin in serum and pericardial
fluid was similar in both Groups A and B.
There was no correlation between the level
of serum VEGF and endostatin (r = 0.15, p =0.47).
No correlation was found between pericardial
fluid VEGF and endostatin (r = 0.39, p =0.06). There
were no significant differences in serum VEGF or
endostatin with respect to gender, diabetes mel-
litus, hypertension, smoking, acute coronary syn-
drome, or ejection fraction.
Discussion
This study demonstrated that the concentration
of serum VEGF in patients with significant CAD
Figure 1. Serum (S) and pericardial fluid (P) levels of: (A) vascular
endothelial growth factor (VEGF); and (B) endostatin in coronary
artery disease (CAD) and non-CAD patients. Error bars indicate ±
standard deviation.
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Figure 2. Serum (S) and pericardial fluid (P) levels of: (A) vascular
endothelial growth factor (VEGF); and (B) endostatin in Group A
and Group B patients with significant coronary artery disease. Error
bars indicate ± standard deviation.
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was significantly higher than in patients without
CAD. This finding is consistent with a previous
report of elevated VEGF in patients with CAD.18
The concentration of serum VEGF in Group A
(patients with good collateral circulation) was sig-
nificantly higher than that in Group B (patients
with poor collateral circulation). The concentra-
tion of VEGF in pericardial fluid was similar in
these two groups. The level of VEGF in serum was
higher than that in pericardial fluid. This finding
is also consistent with a previous study.19 These
data indicate that serum VEGF, but not pericardial
fluid VEGF, is associated with good or poor col-
lateral circulation in patients with significant CAD.
This finding is in agreement with data indicating
that VEGF is the most potent angiogenic growth
factor for the stimulation of collateral vessel growth
in myocardial ischemia.20 VEGF has been shown
to be increased in patients with acute myocardial
infarction.15,21 The number of patients with unsta-
ble angina or acute myocardial infarction was
similar in Group A and in this study, suggesting
that the levels of serum or pericardial VEGF were
not affected by these acute conditions. Previous
studies have demonstrated the need for transient
or permanent coronary vessel occlusion as a stim-
ulus for growth factor modulation and collateral
vessel formation.22,23 The present study demonstrat-
ed a higher prevalence of occluded coronary arter-
ies in Group A patients than in Group B patients,
supporting these previous findings.
Alber et al recently reported that plasma VEGF
concentrations do not correlate with the presence,
severity, and extent of CAD.24 In contrast, increased
VEGF concentrations in CAD patients were found
in this study and by Blann et al.18 This discrepancy
is probably attributable to different patient popu-
lations. Patients with recent acute myocardial in-
farction were excluded by Alber et al, but were in-
cluded by Blann et al and in the present study. In
addition, the controls in the study of Alber et al
were referred for coronary angiography because
of chest pain, whereas those in the present study
all had documented valvular heart disease.
This study demonstrated that endostatin con-
centrations in serum and pericardial fluid were
significantly lower in patients with significant
CAD than in those without CAD. However, endo-
statin levels in serum and pericardial fluid were
similar in CAD patients with good or poor collat-
eral circulation. Panchal et al demonstrated that
pericardial fluid endostatin levels were nearly
40% lower in ischemic heart disease patients with
good collateralization compared with poor collat-
eralization.16 In their study, serum levels of en-
dostatin were not measured and control patients
without CAD were not enrolled.16 The discrepancy
between the findings of this study and that of
Panchal et al is probably attributable to differen-
ces in the patient populations. The prevalence rates
of hypertension (60% vs. 85%), smoking status
(42% vs. 77%), and hyperlipidemia (58% vs. 85%)
were all lower in this study than in Panchal et al’s
study. It is not known, however, whether these
risk factors affect endostatin level. The small sam-
ple size and racial differences may also be partial-
ly responsible for the discrepancy between these
two studies. Our study is the first one to demon-
strate lower serum endostatin levels in patients
with significant CAD.
Hypoxia and myocardial ischemia are the
major stimuli that cause increased VEGF expres-
sion.12,14 The potent angiogenic properties of VEGF
are well described. It has beneficial actions besides
inducing new vessel formation.25 VEGF augments
several endothelial cell functions, including nitric
oxide and prostacyclin production, which have
vasodilatory and antiproliferative effects. The ele-
vated VEGF level in patients with significant CAD
may compensate for both the endothelial dysfunc-
tion and the ischemia in these patients. Other an-
giogenic growth factors such as fibroblast growth
factor and inflammatory cytokines are elevated
in patients with ischemic heart disease.26,27 Their
roles in coronary collateral circulation need fur-
ther investigation.
Endostatin is a potent inhibitor of angioge-
nesis.13 Angiogenesis is mediated by a balance of
proangiogenic and antiangiogenic factors that
favor neovascularization.28 Repression of anti-
angiogenic influences, such as endostatin, may fa-
cilitate the process of neovascularization. The pre-
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sent study demonstrated that good or poor collat-
eral circulation was not associated with the serum
or pericardial fluid levels of endostatin. Neovas-
cularization at the capillary level was not visible
on coronary angiography. Therefore, we cannot
exclude the possibility that lower endostatin lev-
els in patients with significant CAD may contri-
bute to myocardial angiogenesis.
In summary, patients with significant CAD
have lower serum and pericardial fluid levels of
endostatin, and higher serum levels of VEGF. Se-
rum VEGF, but not endostatin, is associated with
good or poor collateralization in patients with sig-
nificant CAD.
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